<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03203525</url>
  </required_header>
  <id_info>
    <org_study_id>2014-0357</org_study_id>
    <secondary_id>NCI-2018-01597</secondary_id>
    <secondary_id>2014-0357</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT03203525</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer</brief_title>
  <official_title>A Phase I Study of the NovoTTF-100L(P) System to Enhance Antitumor Activity in Patients With Predominant Hepatic Metastatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and best dose of combination chemotherapy and&#xD;
      bevacizumab, and to see how well they work with the NovoTTF-100L(P) system in treating&#xD;
      participants with cancer that has come back or does not respond to treatment and has spread&#xD;
      to the liver. Drugs used in chemotherapy, such as oxaliplatin, leucovorin, fluorouracil,&#xD;
      pegylated liposomal doxorubicin hydrochloride, and temsirolimus, work in different ways to&#xD;
      stop the growth of cancer cells, either by killing the cells, by stopping them from dividing,&#xD;
      or by stopping them from spreading. Bevacizumab is a monoclonal antibody that may interfere&#xD;
      with the ability of tumor cells to grow and spread. The NovoTTF-100L(P) system is a portable&#xD;
      device that uses electrical fields to stop the growth of tumor cells. Giving combination&#xD;
      chemotherapy and monoclonal antibody therapy while using the NovoTTF-100L(P) system may kill&#xD;
      more tumor cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To define the maximum tolerated doses (MTD) of two established chemotherapy regimens (Arm&#xD;
      A: FOLFOX6 [oxaliplatin, fluorouracil (5FU) and leucovorin (folinic acid)] plus bevacizumab;&#xD;
      and Arm B: pegylated liposomal doxorubicin hydrochloride [liposomal doxorubicin] and&#xD;
      bevacizumab plus temsirolimus [DAT]) in combination with the concurrent use of the&#xD;
      NovoTTF-100L(P) system in patients with predominant hepatic metastases.&#xD;
&#xD;
      II. To define the safety profiles of FOLFOX6 plus bevacizumab or DAT with concurrent&#xD;
      NovoTTF-100L(P) in patients with predominant hepatic metastases.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate clinical response signals to the treatment with FOLFOX6 plus bevacizumab or&#xD;
      DAT with concurrent NovoTTF-100L(P).&#xD;
&#xD;
      II. To assess predictive biomarkers by analyzing baseline molecular mutation status, and&#xD;
      resistant pathways by comparing molecular signatures at baseline versus at time of relapse in&#xD;
      patients who have achieved objective responses.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study. Participants are assigned to 1 of 2 arms.&#xD;
&#xD;
      ARM A: Participants receive oxaliplatin, leucovorin, and fluorouracil via pump over 46 hours&#xD;
      beginning on day 1, bevacizumab intravenously (IV) over 30-90 minutes on days 1 and 15, and&#xD;
      use NovoTTF-100L(P) system over 18 hours daily. Courses repeat every 28 days in the absence&#xD;
      of disease progression or unacceptable toxicity.&#xD;
&#xD;
      ARM B: Participants receive bevacizumab IV over 90 minutes on days 1 and 15, pegylated&#xD;
      liposomal doxorubicin hydrochloride IV over 30 minutes-3 hours on days 1 and 15, and&#xD;
      temsirolimus IV over 60-90 minutes on days 1, 8, 15, and 22. Participants also use&#xD;
      NovoTTF-100L(P) system over 18 hours daily. Courses repeat every 28 days in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      After the completion of study treatment, patients are followed at 30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 23, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Descriptive statistics will be provided on the grade and type of toxicity by dose level.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Will be assessed by Response Evaluation Criteria in Solid Tumors 1.1. Wilcoxon's Signed-Rank Test and Fisher's exact test will be used for data analysis of continuous variables and categorical variables, respectively. A mixed model accounting for patient effects will be used to analyze longitudinal data (including biomarker data) over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker analysis</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Wilcoxon's Signed-Rank Test and Fisher's exact test will be used for data analysis of continuous variables and categorical variables, respectively. A mixed model accounting for patient effects will be used to analyze longitudinal data (including biomarker data) over time.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Advanced Malignant Neoplasm</condition>
  <condition>Colorectal Carcinoma Metastatic in the Liver</condition>
  <condition>Metastatic Malignant Neoplasm in the Liver</condition>
  <condition>Refractory Malignant Neoplasm</condition>
  <arm_group>
    <arm_group_label>Arm A (FOLFOX6, bevacizumab, NovoTTF-100L[P])</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive oxaliplatin, leucovorin, and fluorouracil via pump over 46 hours on beginning on day 1, bevacizumab IV over 30-90 minutes on days 1 and 15, and use NovoTTF-100L(P) system over 18 hours daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B(bevacizumab,liposomal doxorubicin, DAT, NovoTTF-100L[P])</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive bevacizumab IV over 90 minutes on days 1 and 15, pegylated liposomal doxorubicin hydrochloride IV over 30 minutes-3 hours on days 1 and 15, and temsirolimus IV over 60-90 minutes on days 1, 8, 15, and 22. Participants also use NovoTTF-100L(P) system over 18 hours daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (FOLFOX6, bevacizumab, NovoTTF-100L[P])</arm_group_label>
    <arm_group_label>Arm B(bevacizumab,liposomal doxorubicin, DAT, NovoTTF-100L[P])</arm_group_label>
    <other_name>Anti-VEGF</other_name>
    <other_name>Anti-VEGF Humanized Monoclonal Antibody</other_name>
    <other_name>Anti-VEGF rhuMAb</other_name>
    <other_name>Avastin</other_name>
    <other_name>Bevacizumab awwb</other_name>
    <other_name>Bevacizumab Biosimilar BEVZ92</other_name>
    <other_name>Bevacizumab Biosimilar BI 695502</other_name>
    <other_name>Bevacizumab Biosimilar CBT 124</other_name>
    <other_name>Bevacizumab Biosimilar CT-P16</other_name>
    <other_name>Bevacizumab Biosimilar FKB238</other_name>
    <other_name>Bevacizumab Biosimilar HD204</other_name>
    <other_name>Bevacizumab Biosimilar HLX04</other_name>
    <other_name>Bevacizumab Biosimilar IBI305</other_name>
    <other_name>Bevacizumab Biosimilar LY01008</other_name>
    <other_name>Bevacizumab Biosimilar MIL60</other_name>
    <other_name>Bevacizumab Biosimilar QL 1101</other_name>
    <other_name>Bevacizumab Biosimilar RPH-001</other_name>
    <other_name>Bevacizumab Biosimilar SCT501</other_name>
    <other_name>BP102</other_name>
    <other_name>BP102 Biosimilar</other_name>
    <other_name>HD204</other_name>
    <other_name>Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer</other_name>
    <other_name>Recombinant Humanized Anti-VEGF Monoclonal Antibody</other_name>
    <other_name>rhuMab-VEGF</other_name>
    <other_name>SCT501</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil</intervention_name>
    <description>Given via pump</description>
    <arm_group_label>Arm A (FOLFOX6, bevacizumab, NovoTTF-100L[P])</arm_group_label>
    <other_name>5 Fluorouracil</other_name>
    <other_name>5 Fluorouracilum</other_name>
    <other_name>5 FU</other_name>
    <other_name>5-Fluoro-2,4(1H, 3H)-pyrimidinedione</other_name>
    <other_name>5-fluorouracil</other_name>
    <other_name>5-Fluracil</other_name>
    <other_name>5-FU</other_name>
    <other_name>5FU</other_name>
    <other_name>AccuSite</other_name>
    <other_name>Carac</other_name>
    <other_name>Fluoro Uracil</other_name>
    <other_name>Fluouracil</other_name>
    <other_name>Flurablastin</other_name>
    <other_name>Fluracedyl</other_name>
    <other_name>Fluracil</other_name>
    <other_name>Fluril</other_name>
    <other_name>Fluroblastin</other_name>
    <other_name>Ribofluor</other_name>
    <other_name>Ro 2-9757</other_name>
    <other_name>Ro-2-9757</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>Given via pump</description>
    <arm_group_label>Arm A (FOLFOX6, bevacizumab, NovoTTF-100L[P])</arm_group_label>
    <other_name>folinic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Given via pump</description>
    <arm_group_label>Arm A (FOLFOX6, bevacizumab, NovoTTF-100L[P])</arm_group_label>
    <other_name>1-OHP</other_name>
    <other_name>Ai Heng</other_name>
    <other_name>Aiheng</other_name>
    <other_name>Dacotin</other_name>
    <other_name>Dacplat</other_name>
    <other_name>Diaminocyclohexane Oxalatoplatinum</other_name>
    <other_name>Eloxatin</other_name>
    <other_name>Eloxatine</other_name>
    <other_name>JM-83</other_name>
    <other_name>Oxalatoplatin</other_name>
    <other_name>Oxalatoplatinum</other_name>
    <other_name>RP 54780</other_name>
    <other_name>RP-54780</other_name>
    <other_name>SR-96669</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated Liposomal Doxorubicin Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm B(bevacizumab,liposomal doxorubicin, DAT, NovoTTF-100L[P])</arm_group_label>
    <other_name>ATI-0918</other_name>
    <other_name>Caelyx</other_name>
    <other_name>DOX-SL</other_name>
    <other_name>Doxil</other_name>
    <other_name>Doxilen</other_name>
    <other_name>Doxorubicin HCl Liposomal</other_name>
    <other_name>Doxorubicin HCl Liposome</other_name>
    <other_name>Doxorubicin Hydrochloride Liposome</other_name>
    <other_name>Duomeisu</other_name>
    <other_name>Evacet</other_name>
    <other_name>LipoDox</other_name>
    <other_name>Lipodox 50</other_name>
    <other_name>Liposomal Adriamycin</other_name>
    <other_name>Liposomal Doxorubicin Hydrochloride</other_name>
    <other_name>Liposomal-Encapsulated Doxorubicin</other_name>
    <other_name>Pegylated Doxorubicin HCl Liposome</other_name>
    <other_name>S-Liposomal Doxorubicin</other_name>
    <other_name>Stealth Liposomal Doxorubicin</other_name>
    <other_name>TLC D-99</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temsirolimus</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm B(bevacizumab,liposomal doxorubicin, DAT, NovoTTF-100L[P])</arm_group_label>
    <other_name>CCI-779</other_name>
    <other_name>CCI-779 Rapamycin Analog</other_name>
    <other_name>Cell Cycle Inhibitor 779</other_name>
    <other_name>Rapamycin Analog</other_name>
    <other_name>Rapamycin Analog CCI-779</other_name>
    <other_name>Torisel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Tumor Treating Fields Therapy</intervention_name>
    <description>Use NovoTTF-100L(P) system</description>
    <arm_group_label>Arm A (FOLFOX6, bevacizumab, NovoTTF-100L[P])</arm_group_label>
    <arm_group_label>Arm B(bevacizumab,liposomal doxorubicin, DAT, NovoTTF-100L[P])</arm_group_label>
    <other_name>Alternating Electric Field Therapy</other_name>
    <other_name>TTF</other_name>
    <other_name>TTFields</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with advanced malignancies, either refractory to standard therapy or for&#xD;
             which no effective standard therapy is available, unless the drugs in the protocol are&#xD;
             part of the standard of care for a specific diagnosis&#xD;
&#xD;
               -  Predominant hepatic metastasis is defined as at least 50% of the total tumor&#xD;
                  burden involving the liver&#xD;
&#xD;
               -  An aberrant PI3K pathway such as PIK3CA mutations or PTEN loss, is detected in a&#xD;
                  CLIA (Clinical Laboratory Improvement Amendments)-certified laboratory&#xD;
&#xD;
               -  For patients who are enrolled into the arm of FOLFOX6 plus bevacizumab, they must&#xD;
                  have metastatic colorectal cancer with predominant hepatic metastases&#xD;
&#xD;
               -  For patients who are enrolled into the arm of DAT, they must have predominant&#xD;
                  hepatic metastases harboring an aberrant PI3K pathway&#xD;
&#xD;
          -  Patients must have measurable or evaluable disease, as defined by Response Evaluation&#xD;
             Criteria in Solid Tumors (RECIST) 1.1&#xD;
&#xD;
          -  Women of child-bearing potential (women who are not postmenopausal for at least one&#xD;
             year or are not surgically sterile) and men must agree to use adequate contraception&#xD;
             (e.g., hormonal, barrier device, or abstinence) prior to study entry, for the duration&#xD;
             of study participation, and for 30 days after the last dose of the study agents&#xD;
&#xD;
          -  Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of&#xD;
             0 to 2&#xD;
&#xD;
          -  Neutrophils &gt;= 1,500/uL&#xD;
&#xD;
          -  Platelets &gt;= 100,000/uL&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 x ULN (upper limit of normal) (except patients with Gilbert's&#xD;
             syndrome, who must have a total bilirubin =&lt; 3.0 mg/dL)&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) =&lt; 3 x ULN or =&lt; 5 x ULN if liver metastases persist&#xD;
&#xD;
          -  Serum creatinine =&lt; 1.5 mg/dL or calculated creatinine clearance &gt;= 50 mL/minutes&#xD;
&#xD;
          -  Patients should be able to read and fully understand the requirements of the trial, be&#xD;
             willing to comply with all trial visits and assessments, and be willing and able to&#xD;
             sign an Institutional Reviewed Board (IRB)-approved written informed consent document&#xD;
&#xD;
          -  Patients may receive palliative radiation therapy immediately before or during the&#xD;
             treatment if the radiation therapy is not delivered to the sole target lesions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection requiring intravenous antibiotics, symptomatic congestive heart failure (New&#xD;
             York Heart Association [NYHA] class III or IV), unstable angina pectoris, uncontrolled&#xD;
             systemic hypertension (systolic blood pressure [BP] &gt; 140 mm Hg, diastolic BP &gt; 90 mm&#xD;
             Hg), left ventricular ejection fraction &lt; 50%, active bleeding, or psychiatric&#xD;
             illness/social situations that would limit compliance with study requirements&#xD;
&#xD;
          -  Patients who have not recovered from major surgical procedure, or significant&#xD;
             traumatic injury (i.e., patients still need additional medical care for these issues)&#xD;
&#xD;
          -  History of allergic reactions to the study drugs or their analogs, or any component of&#xD;
             the products, or sensitive to conductive hydrogels used on electrocardiogram (ECG)&#xD;
             stickers or transcutaneous electrical nerve stimulation (TENS) electrodes&#xD;
&#xD;
          -  Any treatment specific for tumor control within 3 weeks of drugs; or within 2 weeks if&#xD;
             cytotoxic agents were given weekly (within 6 weeks for nitrosoureas or mitomycin C),&#xD;
             or within 5 half-lives for targeted agents with half-lives and pharmacodynamic effects&#xD;
             lasting fewer than 4 days (that includes, but is not limited to, erlotinib, sorafenib,&#xD;
             sunitinib, bortezomib, and similar agents), or failure to recover from the toxic&#xD;
             effect of any of these therapies prior to study entry&#xD;
&#xD;
          -  Symptomatic primary tumors or metastasis of brain and/or central nervous system that&#xD;
             are uncontrolled with antiepileptics and requiring high doses of steroids&#xD;
&#xD;
          -  Implanted pacemaker, defibrillator, nerve stimulator or other active electronic&#xD;
             medical devices&#xD;
&#xD;
          -  Corrected QT interval (QTc) is greater than 480 milliseconds (msec) at screening, or&#xD;
             documented clinically significant arrhythmias. The QTc formula Bazett will be used for&#xD;
             assessing subject eligibility&#xD;
&#xD;
          -  History of stroke or transient ischemic attack, peripheral vascular disease, active&#xD;
             gastric or duodenal ulcer, abdominal fistula, gastrointestinal perforation, or&#xD;
             intra-abdominal abscess within 6 months prior to study enrollment&#xD;
&#xD;
          -  Patients with known human immunodeficiency virus infection, active hepatitis B or C&#xD;
&#xD;
          -  Women who are pregnant will be excluded from the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Siqing Fu</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Siqing Fu</last_name>
      <phone>713-792-4318</phone>
      <email>siqingfu@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Siqing Fu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>June 27, 2017</study_first_submitted>
  <study_first_submitted_qc>June 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2017</study_first_posted>
  <last_update_submitted>August 10, 2020</last_update_submitted>
  <last_update_submitted_qc>August 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Endothelial Growth Factors</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Immunoglobulin G</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

